Physician

Mark Douglas Landers, MD

According to 2025 Medicare claims, Mark Landers, MD (NPI: 1952348682) practices cardiac electrophysiology in the Pinehurst-Southern Pines, NC market, with the plurality of this provider's patient population coming from Moore, NC. This provider's primary affiliated billing organization is MCPC-5, LLC (NPI: 1689944514; TIN: 45-4088317) and primary practice location at 28374-8710.

Landers' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,723 traditional Medicare patients, billed 5,934 HCPCS/CPT codes, and received $272,521 in Medicare payments. The top billing code was 93280 (Programming of dual lead pacemaker system). Part D data shows 2,811 prescription claims across 422 beneficiaries totaling $557,780 in drug costs, led by Eliquis (Apixaban). 2022 DME data shows 11 claims. Open Payments data shows 70 records totaling $1,485. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $484,595 to $272,521. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,878 and ending at $1,186.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,959	6,992	$484,595
2016	1,692	6,702	$457,975
2017	2,186	7,516	$460,412
2018	2,225	8,182	$462,633
2019	2,102	8,341	$478,212
2020	1,946	8,035	$435,243
2021	2,069	8,479	$454,430
2022	2,039	7,530	$367,628
2023	1,820	6,715	$313,731
2024	1,723	5,934	$272,521

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	452	4,818	$445,401
2016	491	5,195	$595,074
2017	484	4,753	$568,502
2018	525	4,729	$666,536
2019	509	4,199	$680,130
2020	534	4,315	$759,992
2021	523	4,210	$846,935
2022	484	3,595	$778,908
2023	432	2,978	$662,112
2024	422	2,811	$557,780

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	210	$10,213
2019	N/R	258	$16,233
2020	N/R	37	$2,176
2021	N/R	N/R	N/R
2022	N/R	11	$1,302
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93280	Programming of dual lead pacemaker system	234	351	$45
93294	Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days	201	207	$20
93296	Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days	312	364	$14
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	578	865	$9
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	1,024	1,765	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	329	17,182	$326,755
Xarelto	Rivaroxaban	148	8,209	$147,760
Dofetilide	Dofetilide	224	13,328	$27,784
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	15	990	$5,255
Propafenone Hcl Er	Propafenone Hcl	25	1,590	$4,735

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	70	$1,485	Boston Scientific Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Douglas Landers, MD?

Tedicare shows public-source Medicare data for Mark Douglas Landers, MD (NPI 1952348682), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Douglas Landers, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Douglas Landers, MD?

Mark Douglas Landers, MD is linked to MCPC-5, LLC (billing NPI 1689944514) in the available physician profile data.

Does Mark Douglas Landers, MD have Open Payments data?

Mark Douglas Landers, MD has 70 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.